- Home
- PSHG vs SNTI Comparison
PSHG vs SNTI Comparison
Compare PSHG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | SNTI |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 24.5M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSHG | SNTI |
|---|---|---|
| Price | $1.83 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 192.6K | 96.1K |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $4.76 | $150.00 |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $0.80 |
| 52 Week High | $2.58 | $5.10 |
Technical Indicators
Market Signals| Indicator | PSHG | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 33.05 |
| Support Level | $1.77 | N/A |
| Resistance Level | $2.06 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 18.90 | 1.55 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.